'Workhorse PEF System' Scores CE Mark

Galaxy Medical's Centauri Pulsed Electric Field (PEF) System is approved for the treatment of paroxysmal atrial fibrillation in the European Union and geographies that accept the CE mark.

Amanda Pedersen

September 1, 2022

2 Min Read
CE mark europe flag logo. Euro vector certificate symbol
Image courtesy of Feodora Rosca / Alamy Stock Vector

Galaxy Medical has received a CE mark for its Centauri Pulsed Electric Field (PEF) System and launched its commercial program.

The approval allows the San Carlos, CA-based company to market the new pulsed electric field system for the treatment of paroxysmal atrial fibrillation (AF) in the European Union and geographies that accept the CE mark.

PEF targets arrhythmias by delivering quick bursts of high-voltage, high-frequency energy. Centauri is the first commercially available system to enable pulsed electric field ablation with focal catheters which are used in the majority of cardiac ablation procedures worldwide, Galaxy Medical said.

"From the beginning, we designed Centauri to be the workhorse PEF system for all electrophysiology labs, enabling physicians to maintain use of their favored mapping systems and catheters," said Jonathan Waldstreicher, MD, CEO of Galaxy Medical. "Our goal is to provide a safer and more effective alternative to thermal ablation for all practitioners of cardiac arrhythmia ablation, and the CE mark allows us to offer Centauri to electrophysiologists broadly."

The company touted the following features of the Centauri saystem:

  • The Centauri Connect module allows physicians to perform pulsed electric field ablation procedures with marketed focal catheters and mapping systems without adjustments to workflow or the typical learning curve of training on new catheters.

  • The focal catheter energy is delivered in a monopolar fashion, creating more consistent and deeper lesions.

  • The proprietary Wave1 waveform eliminates microbubbles observed with other pulsed electric field ablation products that can cause brain lesions and strokes, enabling monopolar energy delivery without significant muscle contraction.

  • Centauri offers three energy settings, allowing physicians to choose dosing specific to the target tissue.

Ante Anić, MD, electrophysiology laboratory director at University Clinical Hospital in Split, Coatia, performed the first commercial procedures with Centauri through Intellanav Stablepoint ablation catheters and the Rhythmia HDx mapping system.

"Having observed the progression of Centauri from preclinical studies through the greater than 90% chronic durability for pulmonary vein isolation (PVI) that we achieved in the ECLIPSE-AF study with catheters from all the major manufacturers, the system will be transformational for my daily practice," Anić said. "In just the first few days, we treated de novo atrial fibrillation patients with PVI and recurrence patients with more extensive, beyond PVI lesion sets, demonstrating ultimate flexibility."

Johan Vijgen, head of the electrophysiology division at Jessa Hospital in Hasselt, Belgium, assisted Anić.

"Since the release of the first single-shot PFA catheter, we have been anticipating Centauri's arrival to enable us to deliver PEF through the systems installed in our lab," Vijgen said. "With no adjustment to our workflow, combined with the safety and efficacy in the clinical studies, Centauri will be a central part of my tool kit going forward."

With significant demand, Galaxy said it is partnering with select European centers in the coming months on the initial launch, after which the company plans a broader rollout.

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like